Saturday 17 October 2026
Export SEELQ’s income statement to Excel — free account
Seelos Therapeutics, Inc.
SEELQ Healthcare Biotechnology
Seelos Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.2 million. Revenue growth for three consecutive years, operating cash flow growth for three.
0.00
0.00
NaN
Follow SEELQ
Seelos Therapeutics, Inc. (SEELQ) P/E ratio
Seelos Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 7.1× (April 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| 7 more quarters | Free account |
Against its own ten years
Low 0.0×
High 7.1×
Ten-year median
0.0×
Current reading's percentile
87
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CRIS Curis, Inc. compare | n/m |
| BBLG Bone Biologics Corp. compare | n/m |
| ZVSA ZyVersa Therapeutics, Inc. compare | n/m |
| ATXI Avenue Therapeutics, Inc. compare | n/m |
| LYRA Lyra Therapeutics, Inc. compare | n/m |
| MNTRQ 9 Meters Biopharma, Inc. compare | n/m |
| BTTX Better Therapeutics, Inc. compare | n/m |
| SEELQ Seelos Therapeutics, Inc. | n/m |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)